Catalog
Abilify Alphagan-P 0.15% 5 ml eye drop Anastrozole Andazol Arava Aricept Asacol Augmentin BID BiTiRON T3 and T4 Mix Boldenone Undecylenate BPC-157 Cabaser CARDAROL CJC-1295 without DAC Clomid Delta sleep-inducing peptide Dostinex Enclomiphene EPO - Erythropoietin Fat Targetted Proapoptotic Peptide Filagra - gel shots Follistatin-344 Genopharm HCG GHRP-2 GHRP-6 Gonadorelin HMG - Human menopausal gonadotropin Humulin NPH Humulin Regular IBUTAMOROL Igtropin IGF-1 Long R3 Igtropin IGF-DES Ivermectin 12mg Kenacort-A 40 Letrozole LIGANDROL Liothyronine Sodium Liv.52 Lovegra Melanotan 1 Melanotan 2a Methandienone MGF Mircera Myostatin HMP Nandrolone Ostarol PEG MGF Proscar Radarol Saxenda Sermorelin acetate 2mg SP Nandrolone Sustanon 250 Tadalafil / Apcalis Oral Jelly 20 mg Tadalafil C20 Tamox 20 Tamoxifen Citrate Tenvir EM Testosterone Mix Trenbolone Acetate Triptorelinum Truvada 200 mg/245 mg Vagifem Vagifem 10 mcg Viagra generic ViagrON 100 Xenical Zydena Zymoplex |
Alphagan-P 0.15% 5 ml eye drop
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. WARNINGS AND PRECAUTIONS Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Contamination of Topical Ophthalmic Products After Use: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. DRUG INTERACTIONS CNS Depressants: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP-lowering effect. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines. Monoamine Oxidase Inhibitors: Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Caution is advised in patients taking MAO inhibitors, which can affect the metabolism and uptake of circulating amines. ADVERSE REACTIONS Read more... Our customers also buy with Alphagan-P 0.15% 5 ml eye drop |
Search product: Discounts:
Date: 21 May 1 USD= 0.9300 EUR 1 USD= 0.8200 GBP Telegram / WhatsApp: +380970923164 |